Novozymes A/S

OTCPK:NVZM.F Stock Report

Market Cap: US$30.5b

Novozymes Valuation

Is NVZM.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of NVZM.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Fair Value: NVZM.F ($67.08) is trading above our estimate of fair value ($53.22)

Significantly Below Fair Value: NVZM.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NVZM.F?

Key metric: As NVZM.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NVZM.F. This is calculated by dividing NVZM.F's market cap by their current earnings.
What is NVZM.F's PE Ratio?
PE Ratio48.1x
Earnings€547.00m
Market Cap€26.30b

Price to Earnings Ratio vs Peers

How does NVZM.F's PE Ratio compare to its peers?

The above table shows the PE ratio for NVZM.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.4x
PPG PPG Industries
19.4x9.30%US$24.4b
DD DuPont de Nemours
25x13.55%US$18.0b
RPM RPM International
21.7x11.17%US$14.2b
ECL Ecolab
39.6x11.67%US$78.1b
NVZM.F Novozymes
48.1x17.74%US$196.5b

Price-To-Earnings vs Peers: NVZM.F is expensive based on its Price-To-Earnings Ratio (48.1x) compared to the peer average (26.4x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does NVZM.F's PE Ratio compare vs other companies in the US Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
FFHL Fuwei Films (Holdings)
2.8xn/aUS$27.11m
TANH Tantech Holdings
1.1xn/aUS$6.02m
No more companies available in this PE range
NVZM.F 48.1xIndustry Avg. 25.3xNo. of Companies6PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NVZM.F is expensive based on its Price-To-Earnings Ratio (48.1x) compared to the US Chemicals industry average (25.3x).

Price to Earnings Ratio vs Fair Ratio

What is NVZM.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NVZM.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio48.1x
Fair PE Ratio25.9x

Price-To-Earnings vs Fair Ratio: NVZM.F is expensive based on its Price-To-Earnings Ratio (48.1x) compared to the estimated Fair Price-To-Earnings Ratio (25.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NVZM.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$67.08
US$73.42
+9.44%
12.55%US$87.28US$58.44n/a17
Jan ’27US$62.47
US$74.02
+18.49%
12.36%US$87.99US$59.71n/a17
Dec ’26US$62.44
US$73.21
+17.26%
12.35%US$86.99US$59.03n/a17
Nov ’26US$60.50
US$72.25
+19.42%
12.03%US$88.38US$58.40n/a17
Oct ’26US$60.31
US$73.30
+21.54%
12.04%US$89.39US$59.70n/a17
Sep ’26US$62.26
US$73.48
+18.03%
11.87%US$89.05US$59.47n/a17
Aug ’26US$64.37
US$78.92
+22.60%
12.86%US$91.05US$61.54n/a17
Jul ’26US$71.75
US$79.63
+10.99%
12.31%US$91.18US$61.47n/a17
Jun ’26US$68.83
US$75.54
+9.74%
11.52%US$87.84US$59.22n/a17
May ’26US$63.57
US$73.36
+15.40%
11.73%US$87.13US$58.69n/a16
Apr ’26US$58.49
US$71.22
+21.76%
11.81%US$86.68US$56.24n/a16
Mar ’26US$60.65
US$68.04
+12.18%
11.26%US$83.19US$53.98n/a16
Feb ’26US$58.73
US$67.89
+15.59%
11.77%US$83.49US$51.94n/a16
Jan ’26US$54.86
US$67.43
+22.90%
11.97%US$83.11US$50.59US$62.4716
Dec ’25US$58.50
US$67.59
+15.54%
11.69%US$81.82US$50.83US$62.4416
Nov ’25US$61.45
US$71.08
+15.68%
11.08%US$81.57US$52.44US$60.5015
Oct ’25US$69.50
US$72.99
+5.02%
10.97%US$83.84US$53.90US$60.3116
Sep ’25US$69.26
US$68.90
-0.51%
11.12%US$80.01US$53.34US$62.2616
Aug ’25US$64.07
US$66.29
+3.47%
10.63%US$78.09US$52.06US$64.3716
Jul ’25US$59.33
US$64.80
+9.22%
10.68%US$77.79US$50.42US$71.7516
Jun ’25US$58.00
US$63.63
+9.71%
9.11%US$72.75US$50.92US$68.8314
May ’25US$57.15
US$61.62
+7.83%
9.16%US$71.51US$50.06US$63.5714
Apr ’25US$57.53
US$60.71
+5.53%
9.62%US$72.32US$49.17US$58.4914
Mar ’25US$56.95
US$59.28
+4.09%
8.55%US$66.78US$47.33US$60.6514
Feb ’25US$53.11
US$57.62
+8.48%
8.21%US$65.24US$47.27US$58.7313
Jan ’25US$54.99
US$56.93
+3.52%
8.05%US$63.31US$48.00US$54.8613
US$74.87
Fair Value
10.4% undervalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/15 00:15
End of Day Share Price 2026/01/15 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novozymes A/S is covered by 33 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sebastian SatzBarclays
Cezara LozneanuBarclays
Alexander SloaneBarclays